Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wilson Smith

Critical Care Medicine Spartanburg, SC Medical Doctor

NPI 1982675625 CMS profile 316794

2030 N Church Place, Spartanburg, SC 29303

Open in the dashboard

General payments

$17,179

767 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wilson Smith of Spartanburg, SC is reported in the CMS Open Payments database as having received $17,179 across 767 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,067 128
2024 General $2,974 108
2023 General $2,749 120
2022 General $2,524 116
2021 General $2,241 106
2020 General $1,441 83
2019 General $2,183 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wilson Smith
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Wilson Smith were reported at $3,067. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Wilson Smith Critical Care Medicine median Middle half National median
2019 $2,183 $149 $51–$535 $163
2020 $1,441 $110 $30–$325 $114
2021 $2,241 $125 $34–$403 $132
2022 $2,524 $157 $49–$582 $149
2023 $2,749 $162 $56–$621 $160
2024 $2,974 $168 $53–$634 $164
2025 $3,067 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,269 63 payments
  2. GlaxoSmithKline, LLC. $2,169 114 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,928 79 payments
  4. Grifols USA, LLC $1,088 57 payments
  5. Insmed, Inc. $991 53 payments
  6. Actelion Pharmaceuticals US, Inc. $916 31 payments
  7. Electromed, Inc. $852 63 payments
  8. Gilead Sciences, Inc. $739 38 payments
  9. Harmony Biosciences LLC $665 38 payments
  10. Regeneron Healthcare Solutions, Inc. $572 20 payments
  11. Other $4,991 211 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,031 761 payments
  2. Education $149 6 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,213 74 payments
  2. Prolastin-C Liquid $1,004 53 payments
  3. OFEV $967 39 payments
  4. OPSUMIT $893 30 payments
  5. Arikayce $865 50 payments
  6. FASENRA $749 12 payments
  7. UPTRAVI $704 24 payments
  8. SMARTVEST $625 48 payments
  9. TEZSPIRE $619 21 payments
  10. Sunosi $537 15 payments
  11. Other $9,676 429 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

2,698

Median for Pulmonary Disease: 936

Drug cost

$2,048,244

Median for Pulmonary Disease: $487,987

Branded share of claims

67.9%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 428 $397,623
Xyrem Sodium Oxybate Brand 11 $232,705
Xywav Sodium,calcium,mag,pot Oxybate Brand 11 $223,841
Sodium Oxybate Generic 12 $219,844
Ofev Nintedanib Esylate Brand 15 $195,664
Wakix Pitolisant Hcl Brand 15 $155,091
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 188 $144,300
Breo Ellipta Fluticasone/Vilanterol Brand 249 $139,490
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 13 $113,201
Eliquis Apixaban Brand 83 $55,887

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$162,134

Of which drugs: $8,809

Medicare patients

728

Average age 75

Services billed

3,564

349 women, 379 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 40%
Chronic kidney disease 38%
Ischemic heart disease 36%
Atrial fibrillation 36%
COPD 35%
Heart failure 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 17 18 $4,910
Vaccine for influenza for injection into muscle 90653 Office 46 46 $3,682

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $306
  • GENZYME CORPORATION $107
$413 — —
LUMRYZ
  • Avadel CNS Pharmaceuticals, LLC $307
$307 — —
AREXVY
  • GlaxoSmithKline, LLC. $249
$249 — —
Sunosi
  • Axsome Therapeutics, Inc. $226
$226 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $216
$216 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

767 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record